Recent development in the design of sialyltransferase inhibitors.
Sialylation at the non-reducing end of glycoconjugates is an important biological process in cellular recognitions, tumor metastases, and immune responses, which are mediated by a family of enzymes known as sialyltransferases. Inhibition of sialyltransferases may prove useful in elucidating the biological functions of sialylation and may have therapeutic applications. This review summarizes the recent development in this field with particular focus on the strategies used for the design of carbohydrate mimetics and the structure-activity relationships of substrate-based sialyltransferase inhibitors.
Wang
Xiaofang
X
State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Science, Peking University, Xue Yuan Road #38, Beijing 100083, PR China.
Zhang
Li-He
LH
Ye
Xin-Shan
XS
D004791:Enzyme Inhibitors / Q000138:chemical synthesis* / Q000494:pharmacology; D012799:Sialyltransferases / Q000037:antagonists & inhibitors*
D004791:Enzyme Inhibitors; D012799:Sialyltransferases